Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-2231 in Advanced Solid Tumors
NCT05791474Phase 1Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of ATI-2231 in solid tumor (advanced stage), sponsored by Washington University School of Medicine. Primary endpoint: Number of participants experiencing adverse events. Planned start Nov 2023; status: withdrawn.
02
Drugs
ATI-2231
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05791474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05791474.